Evidence map›Paper›PMID 39857620›Full record

ReviewBiomedicines2024

Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of the Efficacy of Mesenchymal Stem Cells, Neural Stem Cells, and Induced Pluripotent Stem Cells.

Lauren Frawley, Noam Tomer Taylor, Olivia Sivills, Ella McPhillamy, Timothy Duy To, Yibo Wu, Beek Yoke Chin, Chiew Yen Wong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Biochemistry and biophysics reports · 2026
    Review
  6. Review
  7. Article
  8. Synaptic Vesicle Exocytosis and Endocytosis in Motor Nerve Endings of Transgenic Mice Modeling Amyotrophic Lateral Sclerosis upon Antioxidant Treatment and Gene-Cell Therapy.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2025
    Article
  9. Review
  10. Review
  11. Artificial intelligence in dysphagia assessment: evaluating lingual muscle composition in head and neck cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lauren FrawleySchool of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong 2500, Australia.
Noam Tomer TaylorSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney 2052, Australia.
Olivia SivillsSchool of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong 2500, Australia.ORCID 0009-0005-8117-6562
Ella McPhillamySchool of Medical, Indigenous and Health Sciences, University of Wollongong, Wollongong 2500, Australia.
Timothy Duy ToSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney 2052, Australia.ORCID 0009-0003-7660-584X
Yibo WuSchool of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney 2052, Australia.
Beek Yoke ChinSchool of Health Sciences, IMU University, Kuala Lumpur 57000, Malaysia.
Chiew Yen WongSchool of Health Sciences, IMU University, Kuala Lumpur 57000, Malaysia.ORCID 0000-0003-0534-6206

Funding

Australian Government New Colombo Plan (NCP) scheme Australian Government New Colombo Plan (NCP) scheme
6 · The paper itself

Abstract

BACKGROUND/

objectives

methodsThis review evaluates the efficacy of three stem cell types in ALS treatment: mesenchymal stem cells (MSCs), neural stem cells (NSCs), and induced pluripotent stem cells (iPSCs).

resultsMSCs, derived from various tissues, show neuroprotective and regenerative qualities, with clinical trials suggesting potential benefits but limited by small sample sizes and non-randomised designs. NSCs, isolated from the fetal spinal cord or brain, demonstrate promise in animal models but face functional integration and ethical challenges. iPSCs, created by reprogramming patient-specific somatic cells, offer a novel approach by potentially replacing or supporting neurons. iPSC therapy addresses ethical issues related to embryonic stem cells but encounters challenges regarding genotoxicity and epigenetic irregularities, somatic cell sources, privacy concerns, the need for extensive clinical trials, and high reprogramming costs.

conclusionsThis research is significant for advancing ALS treatment beyond symptomatic relief and modest survival extensions to actively modifying disease progression and improving patient outcomes. Successful stem cell therapies could lead to new ALS treatments, slowing motor function loss and reducing symptom severity.

Indexed as

amyotrophic lateral sclerosis (ALS)induced pluripotent stem cells (iPSCs)mesenchymal stem cells (MSCs)neural stem cells (NSCs)regenerative medicinestem cell therapy (SCT)

Identifiers

PMID39857620
PMCPMC11763168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.